FDA clears two ePlex blood culture identification panels

Create PDF

“Receiving FDA clearance for two of our three ePlex BCID panels is an exciting way to end the year,” Hany Massarany, president and chief executive officer of GenMark, said in a press release. “Our third panel is currently under review by FDA and we continue to expect its clearance in the early part of next year. We expect BCID to be a key contributor to our 2019 performance, driving both ePlex placements and assay sales.”